|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/16/23 Syneos Health, Inc. 10-K 12/31/22 136:28M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 6.13M
2: EX-4 Ex-4.9 HTML 53K
4: EX-10 Ex-10.11.12 HTML 292K
5: EX-10 Ex-10.11.13 HTML 377K
6: EX-10 Ex-10.11.14 HTML 359K
7: EX-10 Ex-10.11.15 HTML 275K
8: EX-10 Ex-10.11.16 HTML 392K
9: EX-10 Ex-10.11.17 HTML 433K
3: EX-10 Ex-10.7 HTML 275K
10: EX-21 Ex-21.1 HTML 268K
11: EX-23 Ex-23.1 HTML 35K
12: EX-31 Ex-31.1 HTML 39K
13: EX-31 Ex-31.2 HTML 39K
14: EX-32 Ex-32.1 HTML 38K
15: EX-32 Ex-32.2 HTML 38K
21: R1 Cover Page HTML 105K
22: R2 Consolidated Statements of Income HTML 116K
23: R3 Consolidated Statements of Comprehensive Income HTML 57K
24: R4 Consolidated Statements of Comprehensive Income HTML 41K
(Parenthetical)
25: R5 Consolidated Balance Sheets HTML 143K
26: R6 Consolidated Balance Sheets (Parenthetical) HTML 53K
27: R7 Consolidated Statements of Cash Flows HTML 141K
28: R8 Consolidated Statements of Shareholders' Equity HTML 86K
29: R9 Basis of Presentation and Summary of Significant HTML 171K
Accounting Policies
30: R10 Financial Statement Details HTML 567K
31: R11 Acquisitions, Divestitures, and Investments HTML 146K
32: R12 Long-Term Debt Obligations HTML 175K
33: R13 Leases HTML 243K
34: R14 Derivatives HTML 79K
35: R15 Fair Value Measurements HTML 284K
36: R16 Restructuring and Other Costs HTML 92K
37: R17 Shareholders' Equity HTML 211K
38: R18 Earnings Per Share HTML 98K
39: R19 Income Taxes HTML 436K
40: R20 Revenue from Contracts with Customers HTML 47K
41: R21 Segment Information HTML 170K
42: R22 Operations by Geographic Location HTML 109K
43: R23 Concentration of Credit Risk HTML 42K
44: R24 Related-Party Transactions HTML 50K
45: R25 Commitments and Contingencies HTML 49K
46: R26 Share-Based Compensation HTML 238K
47: R27 Employee Benefit Plans HTML 62K
48: R28 Basis of Presentation and Summary of Significant HTML 232K
Accounting Policies (Policies)
49: R29 Basis of Presentation and Summary of Significant HTML 86K
Accounting Policies (Tables)
50: R30 Financial Statement Details (Tables) HTML 593K
51: R31 Acquisitions, Divestitures, and Investments HTML 118K
(Tables)
52: R32 Long-Term Debt Obligations (Tables) HTML 143K
53: R33 Leases (Tables) HTML 246K
54: R34 Derivatives (Tables) HTML 71K
55: R35 Fair Value Measurements (Tables) HTML 281K
56: R36 Restructuring and Other Costs (Tables) HTML 89K
57: R37 Shareholders' Equity (Tables) HTML 199K
58: R38 Earnings Per Share (Tables) HTML 94K
59: R39 Income Taxes (Tables) HTML 420K
60: R40 Segment Information (Tables) HTML 163K
61: R41 Operations by Geographic Location (Tables) HTML 112K
62: R42 Share-Based Compensation (Tables) HTML 214K
63: R43 Employee Benefit Plans (Tables) HTML 50K
64: R44 Basis of Presentation and Summary of Significant HTML 124K
Accounting Policies - Narrative (Details)
65: R45 Basis of Presentation and Summary of Significant HTML 41K
Accounting Policies - Net Cash Pool Position
(Details)
66: R46 Basis of Presentation and Summary of Significant HTML 57K
Accounting Policies - Estimated Useful Lives of
Property and Equipment (Details)
67: R47 Basis of Presentation and Summary of Significant HTML 49K
Accounting Policies - Estimated Useful Lives of
Intangible Assets (Details)
68: R48 Financial Statement Details - Accounts Receivable HTML 59K
and Unbilled Services, net (Details)
69: R49 Financial Statement Details - Narrative (Details) HTML 50K
70: R50 Financial Statement Details - Schedule of Property HTML 59K
and Equipment, Net (Details)
71: R51 Financial Statement Details - Schedule of Goodwill HTML 61K
(Details)
72: R52 Financial Statement Details - Schedule of HTML 57K
Intangible Assets (Details)
73: R53 Financial Statement Details - Schedule of Future HTML 52K
Amortization Expense (Details)
74: R54 Financial Statement Details - Schedule of Accrued HTML 56K
Expenses (Details)
75: R55 Financial Statement Details - Accumulated Other HTML 54K
Comprehensive Loss, Net of Taxes (Details)
76: R56 Financial Statement Details - Tax Effects HTML 61K
Allocated to Each Component of Other Comprehensive
(Loss) Income (Details)
77: R57 Financial Statement Details - Schedule of Other HTML 49K
(Income) Expense, Net (Details)
78: R58 Financial Statement Details - Supplemental Cash HTML 53K
Flow Information (Details)
79: R59 Acquisitions, Divestitures, and Investments - HTML 123K
Narrative (Details)
80: R60 Acquisitions, Divestitures, and Investments - HTML 52K
Preliminary Estimates of Fair Values of Intangible
Assets and Estimated Useful Lives (Details)
81: R61 Acquisitions, Divestitures, and Investments - HTML 80K
Allocation of Consideration Transferred (Details)
82: R62 Acquisitions, Divestitures, and Investments - HTML 48K
Preliminary Estimates of Fair Value of Intangible
Assets and Estimated Useful Lives (Details)
83: R63 Long-Term Debt Obligations - Schedule of Debt HTML 63K
Obligations (Details)
84: R64 Long-Term Debt Obligations - Narrative (Details) HTML 124K
85: R65 Long-Term Debt Obligations - Schedule of Variable HTML 63K
Rate Margins (Details)
86: R66 Long-Term Debt Obligations - Accounts Receivable HTML 66K
Financing Agreement (Details)
87: R67 Long-Term Debt Obligations - Contractual HTML 78K
Maturities of Debt Obligations (Details)
88: R68 Leases - Narrative (Details) HTML 40K
89: R69 Leases - Components of Lease Cost (Details) HTML 52K
90: R70 Leases - Supplemental Balance Sheet Information HTML 49K
Related to Leases (Details)
91: R71 Leases - Supplemental Cash Flow Information HTML 49K
Related to Leases (Details)
92: R72 Leases - Supplemental Cash Flow Information, HTML 45K
Weighted Average (Details)
93: R73 Leases - Maturities of Lease Liabilities (Details) HTML 92K
94: R74 Derivatives - Narrative (Details) HTML 48K
95: R75 Derivatives - Interest Rate Swaps Designated as HTML 64K
Hedging Instruments on Consolidated Balance Sheets
(Details)
96: R76 Fair Value Measurements - Schedule of Assets and HTML 78K
Liabilities Measured at Fair Value on a Recurring
Basis (Details)
97: R77 Fair Value Measurements - Schedule of Assets and HTML 45K
Liabilities Measured at Fair Value on a Recurring
Basis (Parenthetical) (Details)
98: R78 Fair Value Measurements - Reconciliation of HTML 48K
Changes in the Carrying Amount of Contingent
Consideration (Details)
99: R79 Fair Value Measurements - Narrative (Details) HTML 44K
100: R80 Fair Value Measurements - Schedule of Estimated HTML 60K
Fair Value (Details)
101: R81 Restructuring and Other Costs - Schedule of HTML 46K
Restructuring and other costs (Details)
102: R82 Restructuring and Other Costs - Liabilities HTML 62K
Associated with Restructuring and Other Costs
(Details)
103: R83 Shareholders' Equity - Shares of Common Stock HTML 44K
Outstanding (Details)
104: R84 Shareholders' Equity - Narrative (Details) HTML 87K
105: R85 Shareholders' Equity - Repurchase Activity HTML 46K
(Details)
106: R86 Shareholders' Equity - Schedule of Stock by Class HTML 59K
(Details)
107: R87 Earnings Per Share - Schedule of Earnings Per HTML 75K
Share, Basic and Diluted (Details)
108: R88 Earnings Per Share - Narrative (Details) HTML 38K
109: R89 Income Taxes - Schedule of Components of Income HTML 46K
before Provision for Income Taxes (Details)
110: R90 Income Taxes - Schedule of Components of Income HTML 60K
Tax Expense (Benefit) (Details)
111: R91 Income Taxes - Narrative (Details) HTML 79K
112: R92 Income Taxes - Schedule of Effective Income Tax HTML 83K
Rate Reconciliation (Details)
113: R93 Income Taxes - Schedule of Effective Income Tax HTML 43K
Rate Reconciliation (Parenthetical) (Details)
114: R94 Income Taxes - Summary of Valuation Allowance HTML 53K
(Details)
115: R95 Income Taxes - Schedule of Deferred Tax Assets and HTML 83K
Liabilities (Details)
116: R96 Income Taxes - Schedule of Unrecognized Tax HTML 54K
Benefits (Details)
117: R97 Revenue from Contracts with Customers - Narrative HTML 48K
(Details)
118: R98 Segment Information (Details) HTML 75K
119: R99 Segment Information - Narrative (Details) HTML 37K
120: R100 Operations by Geographic Location - Total Revenue HTML 64K
by Geographic Area (Details)
121: R101 Operations by Geographic Location - Long-Lived HTML 52K
Assets by Geographic Area (Details)
122: R102 Concentration of Credit Risk - Narrative (Details) HTML 45K
123: R103 Related-Party Transactions - Narrative (Details) HTML 62K
124: R104 Commitments and Contingencies - Narrative HTML 52K
(Details)
125: R105 Share-Based Compensation - Narrative (Details) HTML 101K
126: R106 Share-Based Compensation - Stock Option Valuation HTML 49K
Assumptions (Details)
127: R107 Share-Based Compensation - Summary of Option HTML 87K
Activity (Details)
128: R108 Share-Based Compensation - Summary of Restricted HTML 77K
Stock Unit Activity (Details)
129: R109 Share-Based Compensation - Summary of Share-Based HTML 43K
Compensation Expense (Details)
130: R110 Employee Benefit Plans - Schedule of Contributions HTML 38K
to Defined Contribution Plan (Details)
131: R111 Employee Benefit Plans - Narrative (Details) HTML 50K
134: XML IDEA XML File -- Filing Summary XML 250K
132: XML XBRL Instance -- synh-20221231_htm XML 6.72M
133: EXCEL IDEA Workbook of Financial Reports XLSX 271K
20: EX-101.CAL XBRL Calculations -- synh-20221231_cal XML 310K
17: EX-101.DEF XBRL Definitions -- synh-20221231_def XML 1.22M
18: EX-101.LAB XBRL Labels -- synh-20221231_lab XML 2.35M
16: EX-101.PRE XBRL Presentations -- synh-20221231_pre XML 1.89M
19: EX-101.SCH XBRL Schema -- synh-20221231 XSD 298K
135: JSON XBRL Instance as JSON Data -- MetaLinks 752± 1.25M
136: ZIP XBRL Zipped Folder -- 0000950170-23-002928-xbrl Zip 1.40M
| EX-31 |
Exhibit 31.2
CERTIFICATIONS
I, Jason Meggs, certify that:
1. I have reviewed this Annual Report on Form 10-K of Syneos Health, Inc. (the “registrant”);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: February 15, 2023
/s/ Jason Meggs |
Chief Financial Officer |
(Principal Financial Officer) |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed as of: | 2/16/23 | 8-K | ||
| Filed on: | 2/15/23 | 8-K | ||
| For Period end: | 12/31/22 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/27/23 Syneos Health, Inc. DEFM14A 1:2.4M Donnelley … Solutions/FA 6/27/23 Syneos Health, Inc. PRER14A 2:2.5M Donnelley … Solutions/FA 6/15/23 Syneos Health, Inc. PREM14A 6/14/23 2:2.3M Donnelley … Solutions/FA 5/10/23 Syneos Health, Inc. 10-Q 3/31/23 88:10M Donnelley … Solutions/FA |